In recent years, combing with MEK and CDK4 inhibitor has more inhibitory proliferation effect for pancreatic ductal adenocarcinoma and RAS mutant colorectal cancer [42, 43]. This evidence concerns the gene MAP2K7 and pancreatic ductal adenocarcinoma.